Expression of adipocyte differentiation-related protein (ADFP), residing on the surface of lipid droplets, correlates to hepatic fat storage. In the context of consequences and treatment of metabolic disorders, including hepatic steatosis, it is imperative to gain knowledge about the regulation of the human ADFP gene. The nuclear receptor liver-X-receptor (LXR) is a key regulator of hepatic fatty acid biosynthesis and cholesterol homeostasis as well as a potential drug target. Here, we report that two synthetic LXR ligands differently regulate human ADFP expression. The partial
patic TG content, are resistant to diet-induced fatty liver, and have increased hepatic insulin sensitivity (Chang et al., 2006; Varela et al., 2008) . Furthermore, in hepatic cells in culture, overexpression of ADFP increases intracellular TG storage, whereas inhibition of ADFP expression decreases the amount (Magnusson et al., 2006) . Thus, the expression of ADFP correlates to fat storage in the liver.
In pharmaceutical strategies aimed at finding remedies for metabolic disorders, members of the nuclear receptor (NR) family of proteins, including liver-X-receptors (LXRs), have emerged as potential drug targets (Makishima, 2005; Michael et al., 2005) . A wealth of data demonstrates the importance of LXR in the context of cholesterol homeostasis and that pharmacological activation of LXRs has beneficial antiatherogenic effects (Joseph and Tontonoz, 2003) . However, a severe side effect is induction of hypertriglyceridemia and hepatic steatosis, largely as a result of LXR activation of SREBP1c, a key regulator of lipogenic genes in the liver (Grefhorst et al., 2002) . There are two LXR isoforms, LXR␣ (NR1H3) and LXR␤ (NR1H2); LXR␣ is highly expressed in the liver and is thus suggested to be the mediator of the adverse effects.
Endogenous LXR ligands are oxidized cholesterol derivatives and oxysterols, and the LXRs form obligate heterodimers with the retinoid X receptors (RXRs) and bind LXR response elements (LXREs) in target genes containing direct repeats (DR) of the prototypical sequence AGGTCA separated by four nucleotides (DR4) or by one nucleotide (DR1); an inverted repeat separated by one nucleotide has also been identified as an LXRE (Varga and Su, 2007) . The synthetic dual LXR␣/␤ agonists T0901317 (Schultz et al., 2000) and GW3965 (Collins et al., 2002) have been widely used to explore LXR biology. It has been found, however, that T0901317 is also a very potent pregnane-X-receptor (PXR; NR1I2) ligand (Mitro et al., 2007) . Activation of the bile acid sensor, the farnesoid-X-receptor (FXR; NR1H4) by T0901317 has also been demonstrated (Houck et al., 2004) .
In a recent study on primary human hepatocytes, we could show, as expected, that exposure to GW3965 increased TG accumulation, and genome wide expression profiling suggested induction of the ADFP gene. Indeed, we could confirm increased ADFP mRNA expression in response to GW3965, which correlated to increased ADFP protein levels (Kotokorpi et al., 2007) . In the present study, we have shown that the human ADFP gene is a direct LXR target gene and is differentially regulated by the synthetic LXR ligands GW3965 and T0901317.
Materials and Methods
Cell Cultures. Human primary hepatocytes were isolated from resected or unused donor liver tissue essentially as described previously (Strom et al., 1996) . Primary cells were seeded onto biomatrix-coated dishes and cultured as described previously (Kotokorpi et al., 2007) . Willams' E medium (Invitrogen, Paisley, Scotland, UK) supplemented with antibiotics and 3 nM insulin (Actrapid; NovoNordisk A/S, Denmark) was used. HepG2 and HeLa cells from the American Type Culture Collection (Manassas, VA) and Huh7 cells originating from JCRB Cell Bank (Osaka, Japan) were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with penicillin (100 U/ml), streptomycin (100 g/ml), L-glutamine (2 mM), and 10% fetal bovine serum under 5% CO 2 at 37°C. HepG2 cells were serum-deprived for 5 h before ligand treatment for 18 h, unless otherwise indicated. Human primary hepatocytes were treated with ligands for 18 h. Cycloheximide, GW3965, T0901317, 9-cis-retinoic acid (9c-RA), and SR12813 were from Sigma-Aldrich. GW4064 was a generous gift from Dr. Tim Willson (GlaxoSmith Kline, Research Triangle Park, NC).
Plasmid Constructs. A 279-bp region containing a putative LXRE in the human ADFP 3Ј-UTR was cloned into pGL3 promoter (Promega, Nacka, Sweden) using the SacI and XhoI sites [LXRE(279c) ]. Likewise, an 817-bp region in the 5Ј-flanking region containing two potential LXREs was cloned into pGL3 promoter using the XhoI and MluI sites [LXRE(817aϩ/a)]. Primers used were forward, actagagagctcACCCAGTCTCTACTAAAAACATA; reverse, tagcagctcgagATGGCGCAATCTCAGCTCACT for LXRE(279c), and forward, aacgatacgcgtTTGAGATGGAGTCTTGCACCTGTTG; reverse, atattcctcgagTGAGATGGAGTCGCACTCTGTTGC for LXRE(817aϩ/a). Lower-case letters indicate nucleotides introduced for cloning purposes. The QuikChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used to make the constructs LXRE(279c)M2 and LXRE(279c)M3 in which the putative LXRE in the LXRE(279c) was mutated (Fig. 8B) . The 2ϫ(DR4) control plasmid harbors two classic LXREs (AGGTCAtttcAGGTCA) spaced by 64 nucleotides cloned into the MluI and BglII sites in the pGL3promoter plasmid. Human fulllength LXR␣, LXR␤, and RXR␣ were cloned into the pSG5 vector (Stratagene) and were generous gifts from Tomas Jakobsson (Dept. of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden). All constructs were verified by sequencing.
RNA Analysis. Total RNA was isolated using the RNeasy kit (QIAGEN, Valencia, CA). Approximately 500 ng of RNA was reversetranscribed using the SuperScript II reverse transcriptase kit (In- vitrogen). Quantitative real time-polymerase chain reaction (qRT-PCR) was performed using the Fast SYBR Green master mix (Applied Biosystems, Foster City, CA) and amplified in an ABI Prism 7500 Sequence detector. Primers were designed using Primer Express software (Applied Biosystems), and primer sequences are available on request. Relative changes were calculated by the comparative method using 18S as the reference gene.
Transfections. HeLa and Huh7 cells grown in 24-well plates in 5% fetal bovine serum were transfected using FugeneHD (Roche Applied Science) at a ratio of 2:5 (DNA/FugeneHD). Luciferase reporter vector (100 ng) and 10 ng of each nuclear receptor DNA were added per well, and transfections were continued for 5 to 6 h. Cells were treated with 5 M GW3965, 1 M T0901317, or vehicle in serum-free media for 24 h. Cells were lysed with Passive Lysis Buffer (Promega) and Luciferase activity was measured using the Luciferase assay kit (BioThema AB, Handen, Sweden).
Chromatin Immunoprecipitation Assay. Human primary hepatocytes were treated for 1.5 h with 5 M GW3965 while HepG2 cells were treated for 4 h with ligands as indicated in Fig. 7 . Before ligand treatment, HepG2 cells were starved in serum-free media overnight. Approximately 40 ϫ 10 6 primary hepatocytes and 20 ϫ 10 6 HepG2 cells were cross-linked for 15 min at room temperature by adding 1% formaldehyde-containing solution. In HepG2 cells, crosslinking was stopped by adding glycine to a final concentration of 125 mM for 5 min. Cells were then rinsed with phosphate-buffered saline, harvested, and centrifuged at 1000 rpm for 5 min at 4°C. Pellets were resuspended in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris, 1 mM phenylmethylsulfonyl fluoride, and leupeptin/pepstatin A/aprotinin at 5 g/ml, pH 8.1) and rotated for 10 min at 4°C. The nuclei were collected by centrifugation, resuspended in wash buffer, and rotated again. Washed nuclei were centrifuged and resuspended in ChIP buffer (0.01% SDS, 1.1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, and leupeptin/pepstatin A/aprotinin at 5 g/ml, pH 8.1) and subsequently sonicated, leading to DNA fragment sizes of 0.2 to 0.8 bp. Samples were cleared by centrifugation at 14,000 rpm for 10 min at 4°C. Ten percent of the cleared supernatant was used as the input, and the remaining volume was immunoprecipitated with antibodies against RXR, CBP/p300, Pol II from Santa Cruz Biotechnology (Santa Cruz, CA) or a pan-LXR antibody (Jakobsson et al., 2009 ). The immunoprecipitates were analyzed with qRT-PCR using the following primers: ADFP promoter: forward, GTGCCCGAGGGT-GACACT; reverse, CGCACTCACCGACGGACT. ADFP DR4 type c: forward, CTTGGTAGCTCACGGCCTG; reverse, GGCCTCTC-CTGACCTCTTGAT.ADFPDR4typeb:forward,AATAGGCCAGGC-GCTGTG; reverse, TTGTAGAGAAAGGGTTTCACGTTG. ADFP DR4 typ a: forward, GACTCACGCCTGTAATCCAA; reverse, GAGTAGCTGGGATTACAGGAG. ADFP DR4 typ a (ϩ): forward, GACTCACGCCTGTAATCCA; reverse, GAGTAGCTGGGATTA-CAGGTG. ABCA1: forward, TGCTTTCTGCTGAGTGACTGA; reverse, CAATTACGGGGTTTTTGCCG.
Statistics. Values are presented as the mean Ϯ S.D. Prism software (GraphPad Software Inc., San Diego, CA) was used for statistical analyses. Comparisons between groups were made using Student's t test or one-way analysis of variance followed by Neuman-Keul's test when multiple comparisons were made. Samples were considered significantly different at P Ͻ 0.05.
Results

GW3965 but Not T0901317
Regulates ADFP Gene Expression in Human Hepatocytes. Our previous study showed that exposure of primary human hepatocytes to 2 M GW3965 induces the mRNA levels of ADFP and SREBP1c, and that increased ADFP mRNA correlated to increased ADFP protein. In this study, we confirm that ADFP is induced by GW3965 ( Fig. 1) . In several independent experiments using primary human hepatocytes, we were surprised to observe that the more potent LXR agonist T0901317 (which, however, is less specific than GW3965) induced SREBP1c as expected but unexpectedly failed to induce ADFP ( Fig. 1, A and B) . In dose-response experiments in primary human hepatocytes, both ADFP and SREBP1c were dose-dependently induced by GW3965 (Fig. 1, C 
and D).
To further investigate this unexpected observation, and possibly taking advantage of this difference in exploring the regulation of the ADFP gene, we used the human hepatic cell line HepG2. Consistent with the observations in primary hepatocytes, only GW3965 induced ADFP, whereas both ago- nists dose-dependently and with similar efficacy induced SREBP1c in HepG2 cells (Fig. 1, E and F) .
The ADFP Gene Is a Direct LXR Target Gene. As shown in Fig. 2 , increased levels of ADFP and SREBP1c mRNA in HepG2 cells were observed after 3 and 6 h, respectively, of GW3965 exposure (5 M). The induction of ADFP by GW3965 was maximal at 6 h and did not differ between 6 and 30 h ( Fig. 2A) . In contrast, SREBP1c levels were not significantly increased until 19 h of exposure and continued to increase up to 10-fold at 30 h of exposure (Fig. 2B) . T0901317 exposure up to 30 h did not induce ADFP (data not shown).
To examine whether the GW3965-induced expression of ADFP was sensitive to inhibition of ongoing protein synthesis, cells were cotreated with the protein synthesis inhibitor cycloheximide (CHX) and GW3965. In primary human hepatocytes, CHX did not affect the GW3965 induction of ADFP or SREBP1c (Fig. 2, C and D) . This is consistent with a direct effect of GW3965 on both genes. Similar results were obtained in HepG2 cells (data not shown). Taken together, the data suggest that LXR regulates ADFP gene expression at the transcriptional level.
PXR, FXR, and RXR Activation Do Not Modulate ADFP Gene Expression. That GW3965 but not T0901317 induced the ADFP gene raised the question of whether the described previously non-LXR-mediated effects of T0901317 (i.e., activation of PXR and FXR) (Houck et al., 2004; Mitro et al., 2007) , was responsible for the difference. This made us investigate whether induction of ADFP in HepG2 cells by GW3965 was affected by simultaneous treatment with specific ligands to PXR or FXR. Treatment with the PXR agonist SR12813 (0.1-2 M) or the FXR agonist GW4064 (0.1-1 M) alone had no effect on SREBP1c expression (Fig. 3 and data not shown). However, the PXR ligand SR12813 potentiated the inducing effect of GW3965 on SREBP1c (Fig. 3B ). The PXR ligand had no effect on the expression of ADFP; in contrast, the FXR-specific ligand, GW4064, induced the expression of ADFP, an effect that seemed additive to the effect of GW3965 (Fig. 3A) . Both SR12813 and GW4064 affected the expression of known target genes; Cyp7A1 was downregulated by GW4064 and Cyp3A4 was induced by SR12813 (data not shown). These results show that the lack of effect of T0901317 on ADFP expression was not due to concurrent activation of LXR and PXR or FXR.
The LXR/RXR heterodimer, conveying a classic LXRmediated response, is in certain genes activated by ligands for either receptor; synergistic and additive effects on target gene induction have been demonstrated (Li et al., 2002; Antonio et al., 2003) . The RXR ligand 9c-RA did not potentiate the effect of GW3965 on ADFP expression in HepG2 cells but potentiated the GW3965 effect on SREBP1c expression (Fig. 4) .
Putative LXRE Sequences in the ADFP Gene. In an attempt to find putative LXREs in the ADFP gene, we used predictive response element modeling (Sandelin and Wasserman, 2005; Varga and Su, 2007) . Thirty-one putative LXR binding sites, representing 21 DR4, three DR1 elements, and seven inverted repeats separated by one nucleotide, were found with ⌬log scores ranging from 0.66 to 3.74 in the nuclear hormone receptor scan (Sandelin and Wasserman, 2005) . Five of the suggested DR4 elements had the sequence GGATCAn 4 AGGTCA, denoted type a, with ⌬log scores ranging from 3.00 to 3.16. This type of DR4 has previously been identified as a low-affinity nonresponsive LXR-binding element (Laffitte et al., 2001; Li et al., 2002) or as a negative LXRE (Wang et al., 2008) . Five additional putative binding elements with ⌬log scores Ͼ3 were revealed; four of these had the sequence AGATCAn 4 AGGTCA (denoted type b), and one had the sequence AGGTCAn 4 AGGCCA presenting the highest ⌬log score, 3.74 (denoted type c). In Fig. 5 , showing a schematic presentation of the human ADFP gene, from Ϫ20 kb upstream of the first exon to 5 kb downstream of the last exon, the putative LXREs with delta log scores Ͼ3 (type a, b, and c) are indicated. A peroxisome proliferator response element (PPRE) in the ADFP gene (Targett-Adams et al., 2005) at Ϫ2.3 kilobase pairs is also indicated in Fig. 5 . In the LXR␣ gene, the low-affinity nonresponsive LXRE elements, here denoted type a, exist within Alu elements (Li et al., 2002) ; we found that nine of the ten putative LXREs (a, b, and c type) in the human ADFP existed in regions with Ն78% homology to an AluY element (Batzer and Deininger, 2002) .
LXR Directly Regulates the ADFP Gene via LXREs in the 3-UTR and the 5-Flanking Regions.
To further characterize the binding of LXR to the putative LXREs in the human ADFP gene, ChIP assays were performed on samples from human primary hepatocytes. Upon GW3965 stimulation, LXR and RXR were enriched in the 3Ј-UTR containing the DR4 type c, but not in the adjacent region containing the DR4 type b (Fig. 6, A and B) . In addition, upon GW3965 stimulation, an interaction of LXR and RXR was detected at the promoter of the ADFP gene (Fig. 6C) . Furthermore, Pol II and the nuclear receptor coactivators CBP and p300 were recruited to the promoter upon its interaction with the 3Ј-UTR DR4 type c, but not with the DR4 type b (Fig. 6, A-C) . We also analyzed the recruitment of LXR and RXR to the two most proximal DR4 type a elements in the 5Ј-flanking region (Fig. 6, D and E) . Although there were identical DR4 repeats in the two elements, recruitment was only to the most proximal element residing on the minus strand and not to the adjacent upstream element on the plus strand. Interaction of this most proximal DR4 type a element with the promoter region was evident by the recruitment of Pol II and CBP/ p300. As a control experiment, we performed ChIP assays on samples from HepG2 cells; upon GW3965 stimulation, LXR, RXR, and Pol II were enriched at the ADFP promoter region and around the 3Ј-UTR DR4 type c; in contrast, upon T0901317 stimulation, no enrichment of Pol II or the LXR/ RXR heterodimeric partners was observed on the promoter (Fig. 7A) . With both synthetic ligands, GW3965 and T0901317, LXR and Pol II were similarly recruited to the promoter of the ABCA1 gene (Fig. 7B) . It is noteworthy that LXR to some extent seems to interact with the promoter region and the 3Ј-UTR DR4 type c also in unstimulated cells (Fig. 6F) , but not to the same degree as in the ABCA1 promoter, where the enrichment was 40-fold in unstimulated cells (Jakobsson et al., 2009) .
DR4-Mediated LXR Responsiveness in Transient Transfections.
To characterize the LXR responsiveness of the putative LXRE in the 3Ј-UTR of the human ADFP gene, a luciferase construct containing a 279-bp fragment encompassing the DR4 type c [LXRE(279c)] was transiently transfected into HeLa cells together with expression plasmids for human RXR␣ and LXR␣ or LXR␤ (Fig. 8A ). Both LXR isoforms conveyed GW3965-activated induction of the luciferase activity. The 2ϫ(DR4) plasmid, harboring two classic LXREs, was similarly induced. Mutation of the putative LXRE in LXRE(279c), LXRE(297c)M2, and LXRE(279c)M3 (Fig. 8B ) mitigated the ligand-mediated induction. In contrast to the response of the endogenous gene, both GW3965 and T0901317 activated the LXRE(279c) construct when transfected into Huh7 cells together with LXR␣ and RXR␣ expression plasmids (Fig.  8C) . Likewise, a luciferase construct containing an 817-bp fragment encompassing the two DR4 type a elements (LXRE(817aϩ/a) was induced by both ligands in Huh7 cells (Fig. 8C) . These data show that the DR4 type c identified in the 3Ј-UTR of the human ADFP gene is a bona fide LXR responsive element and that at least one DR4 element of type a also confers LXR responsiveness.
Discussion
LXR␣ is the predominant receptor subtype in the liver and also the subtype to which adverse effects of LXR activation, including increased TG synthesis, have been attributed; hypertriglyceridemia in mice is evident in numerous studies. In cultured primary human hepatocytes treated with GW3965, TG synthesis is indeed increased, as is the cellular accumulation of TG, whereas the output of very-low-density lipoprotein-TG from the cells is reduced (Kotokorpi et al., 2007) . 
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This is concordant with in vivo studies in monkeys in which pharmacological LXR activation with GW3965 does not result in hypertriglyceridemia (Groot et al., 2005) . Excessive TG not being secreted is bound to accumulate within the cell. In this study, we have identified the human ADFP gene, shown to have a central role in the formation of lipid droplets (Imamura et al., 2002) , as a direct LXR target gene in hepatocytes, supporting the notion that pharmacological LXR activation in humans might lead to hepatic steatosis.
Using published algorithms (Sandelin and Wasserman, 2005; Varga and Su, 2007) , we found several putative LXREs in the human ADFP gene, in particular DR4 elements, which were denoted type a, b, or c (Fig. 5) . In previously experimentally verified positive LXREs, the third position in the first repeat contains a G (30 of 35) or a T (5 of 35) (Varga and Su, 2007) . The DR4 type a and b elements have an A in the third position in the first repeat, and the DR4 type a has previously been characterized as a low-affinity nonresponsive LXRbinding element in the human LXR␣ gene or as a negative LXRE in the human CYP51A1 gene (Laffitte et al., 2001; Li et al., 2002; Wang et al., 2008) . The C in the fourth position of the second repeat of LXRE type c is atypical but has been found in at least two positive LXREs (Landis et al., 2002; Marathe et al., 2006) . Using ChIP analysis on cross-linked chromatin from primary human hepatocytes, it became evident that sequence identity of the hexamer repeats in DR4 elements is not sufficient to determine whether the element binds LXR or not; LXR/RXR was recruited upon GW3965 stimulation to the most proximal DR4 type a element but not to the more distal one in the 5Јflanking region. The two type a elements that we analyzed reside on different strands, and the surrounding sequences are different, which could play a role for this difference. Of the regions harboring the DR4 types b and c that we analyzed, only the region with the type c was found to bind LXR/RXR and associated coactivators. The recruitment of LXR/RXR to the type a element and to the type c element was also associated with Pol II and cofactor recruitment to the promoter. Clearly, the natural context of response elements determines their ability to convey transcriptional regulation. The LXRE types a and c identified in the ADFP gene extend the list of positive LXREs; when cloned upstream of a reporter gene, these elements mediated LXR ligand-dependent activation.
Binding of LXR to the ADFP LXRE type c is not confined to hepatocytes; ChIP assays revealed that LXR was also enriched at the ADFP promoter and the type c element in differentiated THP-1 cells, a human macrophage cell line, upon GW3965 stimulation (data not shown). Thus, LXRmediated regulation of the ADFP gene is not cell-specific in humans. On the other hand, LXR-mediated regulation of the ADFP is likely to be species-specific. It has been shown that LXR activation has no effect on ADFP expression in mice in vivo or in cultured rodent hepatocytes , which is consistent with our previous comparative studies on primary human and rat hepatocytes (Kotokorpi et al., 2007) . This is further corroborated by the absence of the LXRE type c in the 3Ј-UTR of the mouse ADFP gene; i.e., the responsive element is not conserved. In this context, it should be mentioned that the LXRE type c exists within an Alu element, which is highly represented in the human genome but not in rodent genomes.
The finding that T0901317 did not induce ADFP in primary human hepatocytes or in HepG2 cells was most surprising, because GW3965 has been suggested to be a geneselective LXR modulator in the liver and also less potent than T0901317 (Miao et al., 2004) . However, our data are consistent with published data showing that T0901317 has no effect on ADFP expression in a placental cell line of human origin (Tobin et al., 2006) . We were concerned that this was due to the ability of T0901317 to bind and activate PXR and FXR as well (Houck et al., 2004; Mitro et al., 2007) , which possibly could regulate ADFP negatively. However, by cotreatment of HepG2 cells with GW3965 and a specific PXR (SR12813) or FXR (GW4064) ligand, we could exclude this possibility.
GW3965 is considered to be a partial LXR agonist and T0901317 a full agonist, which might be due to differential coactivator and corepressor recruitment (Miao et al., 2004; Albers et al., 2006) . Cell type and promoter-specific differences in coregulator recruitment have been described for other nuclear receptors with different ligands [e.g., the estrogen receptors and the ligands tamoxifen and raloxifen (Shang and Brown, 2002) ]. Although both GW3965 and T0901317 induce an agonist conformation of helix 12, differ- ences in the ligand-binding pocket are observed (Farnegardh et al., 2003) . Whether these differences translate into sequence-specific DNA binding/recognition of the receptor complex is not known, but a distinction like this could explain the difference seen in the regulation of ADFP. Several studies show both ligand-and gene-specific effects conveyed by LXR activation. Studies by Kase et al. (2006) have revealed differential effects on lipid metabolism by the natural LXR agonist 22-hydroxycholesterol and T0901317, suggesting that LXR induction of certain genes is ligand-specific. Furthermore, differential and gene-specific displacement of the nuclear receptor corepressor by T0901317 and GW3965 has been shown (Albers et al., 2006; Phelan et al., 2008) . This indicates that the interplay between LXR and coregulators is ligand-and gene-specific.
It could be postulated that GW3965, but not T0901317, induces an LXR conformation that allows the receptor complex to bind to the identified LXREs in the 3Ј-UTR and in the 5Ј-flanking region of the human ADFP gene and recruit coactivators such as CBP/p300. These distal regulatory elements may come in direct contact with the transcription start site and the general transcription machinery by forming a chromatin loop. The LXR/RXR recruitment in the promoter region and on the LXRE type c, also in non-ligand-stimulated cells (Fig. 6F) , may indicate a pre-existing chromatin loop. Chromatin looping, such as physical interaction between distal enhancers and a promoter, has been described for the LXR-regulated ABCG1 gene, where an enhancer is located in the seventh intron of the gene (Jakobsson et al., 2009) .
In contrast to the endogenous ADFP gene, the LXRE type a and c luciferase reporter constructs, LXRE(817aϩ/a) and LXRE(279c), respectively, were activated by both GW3965 and T0901317. This further supports an LXR-mediated activation of the human ADFP gene, and suggests that the chro- molpharm.aspetjournals.org matin structure is differently modified by the two ligands. In the human ADFP promoter, a functional PPRE has been identified (Targett-Adams et al., 2005) , which is conserved in the murine ADFP gene (Chawla et al., 2003) . A functional Ets/AP-1element has been recognized in the mouse ADFP promoter, and it is suggested that this site, in addition to the PPRE, is crucial for PPAR-mediated activation of the mouse ADFP promoter (Wei et al., 2005) . Likewise, one could imagine that additional elements in the human ADFP gene could contribute to the divergent effects seen by the two synthetic LXR ligands. In addition, hitherto uncharacterized DR4 elements might be involved in the regulation.
Taken together, our results demonstrate that the human ADFP gene is a direct LXR target gene and that different LXR agonists differentially regulate the endogenous gene. The differential mechanisms are not yet clear but call for refined strategies and the use of appropriate experimental models in developing selective LXR agonists for treatment of human metabolic disorders.
